Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Asset Resilience Ratio
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has an Asset Resilience Ratio of 6.25% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Tianjin Zhong Xin Pharmaceutical Group C strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2019)
This chart shows how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Tianjin Zhong Xin Pharmaceutical Group C to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 2TZ market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €500.53 Million | 6.25% |
| Total Liquid Assets | €500.53 Million | 6.25% |
Asset Resilience Insights
- Limited Liquidity: Tianjin Zhong Xin Pharmaceutical Group Corporation Limited maintains only 6.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Industry Peers by Asset Resilience Ratio
Compare Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
China Animal Husbandry Industry Co Ltd
SHG:600195 |
Drug Manufacturers - Specialty & Generic | 3.81% |
Annual Asset Resilience Ratio for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2015–2019)
The table below shows the annual Asset Resilience Ratio data for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.55% | €43.52 Million ≈ $50.88 Million |
€7.84 Billion ≈ $9.17 Billion |
-0.20pp |
| 2018-12-31 | 0.75% | €53.31 Million ≈ $62.32 Million |
€7.11 Billion ≈ $8.31 Billion |
-0.77pp |
| 2017-12-31 | 1.52% | €100.50 Million ≈ $117.50 Million |
€6.62 Billion ≈ $7.74 Billion |
+1.51pp |
| 2016-12-31 | 0.01% | €660.00K ≈ $771.61K |
€6.36 Billion ≈ $7.44 Billion |
-3.29pp |
| 2015-12-31 | 3.30% | €200.00 Million ≈ $233.82 Million |
€6.07 Billion ≈ $7.10 Billion |
-- |
About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and… Read more